Xiga xigaHagaha xiga
Qorshayaasha Xakamaynta Isbeddelka ee FDA ee Qalabka AI
Bulshada
HAGAHA Warshadaha
Xeerka FDA ee Aaladaha Caafimaadka ee AI
In the United States, AI software that diagnoses, treats, or informs care for a patient is usually regulated by the FDA as a medical device.
Dhageyso hagahanAI-waa laga sheekeeyay · ~3 min
Boggaan4 daqiiqo akhri
Dulmar
It reaches the market through one of three main routes: 510(k) clearance, De Novo classification, or premarket approval (PMA). This matters because it decides what evidence a developer must produce, how an AI model can be updated after launch, and how much doctors and patients can trust the tool.
quusid qoto dheer
The FDA regulates software by its intended use, not by the technology inside it. If software is meant to diagnose, treat, prevent, or mitigate disease, it is generally a device; standalone software of this kind is called Software as a Medical Device (SaMD). Devices fall into Class I, II, or III by risk, and the class largely sets the pathway. Most AI-enabled devices reach the market through 510(k) clearance, in which the manufacturer shows substantial equivalence to a legally marketed "predicate" device. When a novel device is low to moderate risk and has no predicate, the De Novo pathway creates a new classification that later devices can use as a predicate. Premarket approval (PMA), the strictest route, is reserved for high-risk Class III devices and usually requires clinical evidence. The FDA's public list of authorized AI-enabled devices now runs to more than a thousand products, most of them in radiology. Not all health software is a device. The 21st Century Cures Act (2016) excludes certain clinical decision support tools. To qualify, the tool must show clinicians the basis for its recommendations so they can review them independently, and it must not analyze medical images or signals. Traditionally, a significant change to a cleared device needs a new submission. The Food and Drug Omnibus Reform Act of 2022 gave the FDA authority to approve predetermined change control plans (PCCPs), and the FDA finalized guidance for AI-enabled devices in December 2024. A PCCP lets a manufacturer make specified, pre-validated changes without filing again. A common misconception is that cleared AI devices learn on their own in the field. Most authorized models are "locked": they change only through controlled, versioned updates. In the EU, the Medical Device Regulation (MDR) classifies software under Rule 11, which puts most diagnostic software in Class IIa or higher and so requires notified body review. The EU AI Act adds high-risk AI obligations for these devices, phasing in later than most of the Act.
Dhaqangelinta Adduunka-dhabta ah
A radiology startup builds software that flags suspected brain bleeds on CT scans and moves them up the reading queue. It gets 510(k) clearance by showing substantial equivalence to a triage tool that is already cleared.
IDx-DR (now LumineticsCore) detects diabetic retinopathy in retinal photos without a specialist reading the image. There was no predicate device, so the FDA authorized it through the De Novo pathway in 2018.
A maker of ECG analysis software submits a predetermined change control plan (PCCP) with its application. The plan describes how the company will retrain the model on new data and what tests each update must pass, so those updates do not each need a new submission.
A company selling the same imaging AI in Europe must get a CE mark under the EU Medical Device Regulation through a notified body. It must also prepare for the EU AI Act, which treats such products as high-risk AI systems.
The Future of FDA Regulation of AI Medical Devices
The main open question is generative AI. Large language models produce open-ended output that is hard to validate the way a fixed classifier is validated. The FDA's Digital Health Advisory Committee held its first meeting on generative AI-enabled devices in November 2024. Expect more attention to monitoring real-world performance after deployment, to transparency about training data, and to greater use of PCCPs as manufacturers learn what the FDA will accept. In Europe, companies face overlapping MDR and AI Act requirements. Guidance on how the two fit together, and whether notified bodies have enough capacity, will shape how quickly AI devices reach patients there.
Ku dhaqangelinta
Maxay muhiim u tahay
- Macnaha iyo xeerarka. Macnaha guud ee warshadaha ayaa go'aamiya in fikradaha AI ay ka badbaadaan xiriirka dhabta ah.
- Xakamaynta tayada. Caqabadaha domain waxay saameeyaan heerarka khaladaadka la aqbali karo iyo moodooyinka kormeerka.
- Xulashada dhismayaasha. Hawlgalinta guusha leh waxay la jaanqaadaysaa awoodda farsamada iyo socodka shaqada safka hore.
Iska ilaali
- Shuruudaha sharciyeedku waxay burin karaan tusaalooyin kale oo xooggan.
- Xogta taariikhiga ah waxa laga yaabaa inay dejiso eexda waxyeellaysa bulshooyinka gaarka ah.
- Nidaamyada dhaxalka ah waxay abuuri karaan carqalado is dhexgalka iyo kharashyo qarsoon.
Tallaabooyinka xiga
- Ka qaybgal khabiirada goobta laga bilaabo qaabaynta dhibaatada ilaa qiimaynta.
- Naqshad habab xisaabeedka iyo dukumentiyada kahor intaan la bilaabin.
- Horey u xaqiiji u hoggaansanaanta iyo waajibaadka badbaadada.
- U soo bax marxalado leh shuruudo joogsi iyo dib u celin cad.
Sii wad Sahaminta
Warqad bilaash ah
Hel warbixinta maalinlaha ah ee AI
Saddex sheeko oo la xaqiijiyay oo AI ah maalin kasta oo shaqo ah, oo lagu qoray Ingiriis fudud. Bilaash had iyo jeer, aan xayaysiis lahayn.
Hal iimayl maalin kasta oo shaqo ah. Ka bax hal gujin. Marna ma iibinno ama ma wadaagno ciwaankaaga.
Is tijaabi
Take the FDA Regulation of AI Medical Devices quiz
Fikrad degdeg ah oo ku saabsan jawaab kasta, iyo shahaado la wadaajin karo oo leh aqoonsi la xaqiijin karo markaad ka gudubto koorso.
Taageer waxbarashada AI bilaashka ah. AI Understanding waa 501(c)(3) aan faa'iido doon ahayn — xayaysiis la'aan, albaab lacag ah ma jiro, had iyo jeer. Samee deeq
Su'aalaha soo noqnoqda
What is FDA Regulation of AI Medical Devices?
In the United States, AI software that diagnoses, treats, or informs care for a patient is usually regulated by the FDA as a medical device. It reaches the market through one of three main routes: 510(k) clearance, De Novo classification, or premarket approval (PMA). This matters because it decides what evidence a developer must produce, how an AI model can be updated after launch, and how much doctors and patients can trust the tool.
What must a manufacturer show to obtain 510(k) clearance?
A 510(k) rests on substantial equivalence to an existing predicate. Most AI-enabled devices reach the market this way.
The FDA authorized IDx-DR, an autonomous AI for diabetic retinopathy, in 2018. Which pathway did it use, and why?
De Novo is for novel low-to-moderate-risk devices with no predicate. Once a device is authorized this way, later devices can use it as a predicate.
What does a predetermined change control plan (PCCP) allow?
A PCCP authorizes planned changes, such as retraining, in advance, along with the protocol used to validate them. Changes outside the plan still need a new submission.
Which three parts make up a PCCP?
A PCCP describes the planned changes, sets out how they will be developed and validated, and assesses their benefits and risks.
Which statement about most FDA-authorized AI devices is accurate?
Most authorized AI models are locked. Updates come as controlled versions, and radiology, not dermatology, accounts for most authorized AI devices.
Sii wad waxbarashada
Tilmaamaha la xidhiidha
Tilmaamayaal badan ayaa loo doortay mawduucan